Severe de-novo palmoplantar and nail psoriasis complicating Nivolumab treatment for metastatic melanoma.
dermatologic therapy
melanoma
psoriasis
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
01
01
2020
revised:
17
03
2020
accepted:
28
03
2020
pubmed:
3
4
2020
medline:
15
5
2021
entrez:
3
4
2020
Statut:
ppublish
Résumé
Nivolumab, a fully human IgG4 immune checkpoint modulator, binds to the programmed cell death 1 (PD-1) receptor on T cells and blocks their inhibition. Thus, it increases the anticancer host immune response by allowing T cells to attack tumor cells. Although anti-PD-1 immunotherapy is typically well accepted, deregulation of immune tolerance caused by nivolumab may determine immune-related adverse events, among which skin toxicities represent the most common. We report a case of severe new-onset palmoplantar and nail psoriasis after receiving nivolumab treatment for metastatic melanoma.
Substances chimiques
Antineoplastic Agents, Immunological
0
Programmed Cell Death 1 Receptor
0
Nivolumab
31YO63LBSN
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13363Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Veronesi G, Scarfì F, Misciali C, et al. An unusual skin reaction in uveal melanoma during treatment with nivolumab: extragenital lichen sclerosus. Anticancer Drugs. 2019;30(9):969-972.
Scarfì F, Melotti B, Veronesi G, et al. Sweet syndrome in metastatic melanoma during treatment with dabrafenib and trametinib. Australas J Dermatol. 2019a;60(3):e242-e243.
Scarfì F, Lacava R, Patrizi A, et al. Follicular psoriasis induced by pembrolizumab in a patient with advanced non-small-cell lung cancer. Int J Dermatol. 2019b;58(8):e151-e152.
Wouters A, Durieux V, Kolivras A, Meert AP, Sculier JP. Bullous lupus under Nivolumab treatment for lung cancer: a case report with systematic literature review. Anticancer Res. 2019 Jun;39(6):3003-3008.
Edwards C, Fearfield L. Nivolumab-induced lichenoid dermatitis occurring in a patient with metastatic melanoma successfully treated with alitretinoin. Clin Exp Dermatol. 2018 Jul;43(5):609-610.
Elosua-González M, Pampín-Franco A, Mazzucchelli-Esteban R, et al. A case of de novo palmoplantar psoriasis with psoriatic arthritis and autoimmune hypothyroidism after receiving nivolumab therapy. Dermatol Online J. 2017 Aug 15;23(8):13030/qt12n4m6pm.
Kato Y, Otsuka A, Miyachi Y, Kabashima K. Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma. J Eur Acad Dermatol Venereol. 2016;30(10):e89-e91.
De Bock M, Hulstaert E, Kruse V, Brochez L. Psoriasis vulgaris exacerbation during treatment with a PD-1 checkpoint inhibitor: case report and literature review. Case Rep Dermatol. 2018 Aug 9;10(2):190-197.
Kaloyannidis P, Al Shaibani E, Mashhour M, Gamil M, Apostolidis I, Al Hashmi H et al. De novo psoriasis vulgaris diagnosed after Nivolumab treatment for refractory Hodgkin's lymphoma, completely resolved after autologous hematopoietic stem cell transplantation Case Rep Hematol. 2018;2018:6215958.
Fattore D, Annunziata MC, Panariello L, Marasca C, Fabbrocini G. Successful treatment of psoriasis induced by immune checkpoint inhibitors with apremilast. Eur J Cancer. 2019 Mar;110:107-109.
Bonigen J, Raynaud-Donzel C, Hureaux J, et al. Anti-PD1-induced psoriasis: a study of 21 patients. J Eur Acad Dermatol Venereol. 2017;31(5):e254-e257.
Dika E, Patrizi A, Ribero S, et al. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma. Eur J Dermatol. 2016;26(3):232-239.